RecruitingPhase 2NCT07025824

Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation

Randomized Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation

Sponsor

Technische Universität Dresden

Enrollment

220 participants

Start Date

Jan 21, 2026

Study Type

INTERVENTIONAL

Conditions

MDS (Myelodysplastic Syndrome)AML (Acute Myeloid Leukemia)

Summary

The aim of this study is to compare the effectiveness and tolerability of two conditioning chemotherapies prior to allogeneic stem cell transplantation. The following will also be investigated: * Survival * Remission and Relapse rate * Engraftment or graft failure * Graft versus Host Disease (GvHD)

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Fludarabine (Flud), a drug called Melphalan (Mel), and others for people with aml (acute myeloid leukemia) and mds (myelodysplastic syndrome). The study is currently recruiting participants at 17 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTreosulfan (Treo)

10 g/m2 intravenous

DRUGMelphalan (Mel)

140 mg/m2 intravenous

DRUGFludarabine (Flud)

30 mg/m2 intravenous

Locations(17)

Universitätsklinikum Aachen, Medizinische Klinik IV

Aachen, Germany

Klinikum Augsburg, Medizinische Klinik II

Augsburg, Germany

Helios Klinikum Berlin Buch, Klinik für Onkologie und Palliativmedizin

Berlin, Germany

Klinikum Chemnitz gGmbH; Klinik für Innere Medizin III

Chemnitz, Germany

Universitätsklinikum Köln, Klinik I für Innere Medizin

Cologne, Germany

Medizinische Fakultät der TU Dresden, Medizinische Klinik und Poliklinik I

Dresden, Germany

Universitätsklinikum Frankfurt, Medizinische Klinik II

Frankfurt am Main, Germany

Universitätsklinikum Greifswald, Klinik und Poliklinik für Innere Medizin C

Greifswald, Germany

Universitätsmedizin Halle (Saale), Klinik für Innere Medizin IV

Halle, Germany

Universitätsklinikum Jena, Klinik für Innere Medizin II

Jena, Germany

Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Innere Medizin II

Kiel, Germany

Universitätsklinikum Leipzig, Klinik und Poliklinik für Hämatologie, Zelltherapie, Hämostaseologie und Infektiologie

Leipzig, Germany

Klinikum der Johannes Gutenberg Universität, III. Medizinische Klinik und Poliklinik

Mainz, Germany

Universitätsklinikum Münster, Medizinische Klinik A, KMT-Zentrum

Münster, Germany

Klinikum Nürnberg, Campus Nord, Klinik für Innere Medizin 5

Nuremberg, Germany

Universitätsklinik Rostock, Klinik und Poliklinik für Innere Medizin, Abt. für Hämatologie/Onkologie

Rostock, Germany

Robert-Bosch-Krankenhaus, Hämatologie, Onkologie und Palliativmedizin

Stuttgart, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07025824

Related Trials

Luspatercept + Darbepoetin in MDS

NCT070962973 locations

CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML

NCT073474181 location

Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN

NCT066908271 location

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

NCT011741082 locations

A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)

NCT07771803